Immunostimulating Interstitial Laser Thermotherapy in Breast Cancer
Launched by CLINICAL LASERTHERMIA SYSTEMS AB · Jan 30, 2017
Trial Information
Current as of May 22, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Have histologically confirmed breast cancer
- • 2. Hormone receptor positive or negative
- • 3. Have assessable tumour by MRI or ultrasound
- • 4. Are patients deemed unfit for surgical excision of tumour under general anaesthetic.
- • 5. Have been given informed verbal and written consent for participation in the trial
- • 6. Have stable hematologic, renal and hepatic functions.
- Exclusion Criteria:
- • 1. Are known to be HIV positive
- • 2. Have active autoimmune disease
- • 3. Are on corticosteroid medication
- • 4. Have evidence of bleeding diathesis or coagulopathy.
About Clinical Laserthermia Systems Ab
Clinical Laserthermia Systems AB (CLS) is a pioneering medical technology company specializing in the development and commercialization of innovative laser-based solutions for the treatment of various medical conditions. Focused on advancing minimally invasive therapies, CLS leverages cutting-edge laser technology to provide effective and precise treatment options in oncology and other fields. The company is committed to enhancing patient outcomes through rigorous clinical trials and research, ensuring safety and efficacy in its products. With a dedicated team of experts and a strong emphasis on innovation, CLS aims to redefine standards in laser therapy and improve the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nottingham, , United Kingdom
Patients applied
Trial Officials
Kristjan S Asgeirsson, MD
Principal Investigator
Nottingham Breast Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials